Summation
- Agricultural engineer and graduate of the CPA (Executive MBA), Laurent Guerci has spent his entire career in information systems, first as the founding director of a company specialized in ERP for agricultural applications, which he sold, then as consulting director in information systems at PWC, and finally as director of various profit centers within the ACTIA industrial Group, where he was in charge of developing new digital activities in France and abroad.
- ABIONYX Pharma’s ambition, in support of its innovative biotherapies strategy, is to digitalise its internal processes, its exchanges with its pharmaceutical partners and to use its data capital through the use of Artificial Intelligence technologies to improve its know-how in pre-clinical and clinical studies and the development of innovative therapies, whether in sepsis, renal diseases or ophthalmology.
- PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant ApoA-I, today announces the appointment of Laurent Guerci as Chief Digital &.
ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant ApoA-I, today announces the appointment of Laurent Guerci as Chief Digital & Innovation Officer.
Agricultural engineer and graduate of the CPA (Executive MBA), Laurent Guerci has spent his entire career in information systems, first as the founding director of a company specialized in ERP for agricultural applications, which he sold, then as consulting director in information systems at PWC, and finally as director of various profit centers within the ACTIA industrial Group, where he was in charge of developing new digital activities in France and abroad.
He will be responsible for carrying out various projects to structure ABIONYX Pharma, in particular the digitalisation of the Group. ABIONYX Pharma’s ambition, in support of its innovative biotherapies strategy, is to digitalise its internal processes, its exchanges with its pharmaceutical partners and to use its data capital through the use of Artificial Intelligence technologies to improve its know-how in pre-clinical and clinical studies and the development of innovative therapies, whether in sepsis, renal diseases or ophthalmology.
